Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Accelerating Nanobody Production using Polyclonal Anti-VHH Antibodies

Accelerating Nanobody Production using Polyclonal Anti-VHH Antibodies

VUMC partners with Batavia to move promising Zika antibody therapy closer to the clinic

VUMC partners with Batavia to move promising Zika antibody therapy closer to the clinic

UC San Diego researchers identify new therapeutic approach to kill cancer cells

UC San Diego researchers identify new therapeutic approach to kill cancer cells

Scientists step closer to an Ebola cure

Scientists step closer to an Ebola cure

Human apolipoprotein E promotes hepatitis B virus infection

Human apolipoprotein E promotes hepatitis B virus infection

New nanovaccine for deadly skin cancer

New nanovaccine for deadly skin cancer

GW Cancer Center selected as first global clinical trial site for high risk cutaneous squamous cell carcinoma

GW Cancer Center selected as first global clinical trial site for high risk cutaneous squamous cell carcinoma

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

Servier chooses Pall as single-source supplier for new biomanufacturing facility

Servier chooses Pall as single-source supplier for new biomanufacturing facility

New study uncovers 3D structure of toxin responsible for C. diff infection

New study uncovers 3D structure of toxin responsible for C. diff infection

Veravas launches advanced solutions to address biotin interference in diagnostic tests

Veravas launches advanced solutions to address biotin interference in diagnostic tests

FDA grants accelerated approval to new treatment for refractory multiple myeloma

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Global study reveals viruses as important cause of childhood pneumonia

Global study reveals viruses as important cause of childhood pneumonia

Stability Testing of Therapeutic Proteins using DLS and Machine Learning

Stability Testing of Therapeutic Proteins using DLS and Machine Learning

New chemoimmunotherapy regimen for aggressive form of lymphoma gets FDA approval

New chemoimmunotherapy regimen for aggressive form of lymphoma gets FDA approval

TEST-1 Using SPR to Confront the Antibody Reproducibility Crisis

TEST-1 Using SPR to Confront the Antibody Reproducibility Crisis

Research suggests new way to improve the efficacy of arthritis drug

Research suggests new way to improve the efficacy of arthritis drug

Experimental antiviral drug completely protects monkeys from Nipah virus

Experimental antiviral drug completely protects monkeys from Nipah virus

NIH announces awards to advance development of vaccines for sexually transmitted infections

NIH announces awards to advance development of vaccines for sexually transmitted infections

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.